Centre for Health Policy, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, 3010, Australia.
Formerly employed by the Australian Centre for the Prevention of Cervical Cancer, Carlton, VIC, 3053, Australia.
BMC Health Serv Res. 2023 Oct 6;23(1):1073. doi: 10.1186/s12913-023-10040-6.
The transition of Australia's National Cervical Screening Program from cytology to a molecular test for human papillomavirus (HPV) (locally referred to as the 'Renewal'), including a longer five-year interval and older age at commencement, significantly impacted all sectors of program delivery. The Renewal had major implications for the roles and requirements of pathology laboratories providing services for the Program. This study aimed to understand the early impacts of the Renewal and its implementation on the pathology sector.
Semi-structured qualitative interviews were conducted with key stakeholders (N = 49) involved in the STakeholder Opinions of Renewal Implementation and Experiences Study (STORIES), 11-20 months after the program transition. A subset of interviews (N = 24) that discussed the pathology sector were analysed using inductive thematic analysis.
Four overarching themes were identified: implementation enablers, challenges, missed opportunities, and possible improvements. Participants believed that the decision to transition to primary HPV screening was highly acceptable and evidence-based, but faced challenges due to impacts on laboratory infrastructure, resources, staffing, and finances. These challenges were compounded by unfamiliarity with new information technology (IT) systems and the new National Cancer Screening Register ('Register') not being fully functional by the date of the program transition. The limited availability of self-collection and lack of standardised fields in pathology forms were identified as missed opportunities to improve equity in the Program. To improve implementation processes, participants suggested increased pathology sector involvement in planning was needed, along with more timely and transparent communication from the Government, and clearer clinical management guidelines.
The transition to primary HPV screening had a significant and multifaceted impact on the Australian pathology sector reflecting the magnitude and complexity of the Renewal. Strategies to support the pathology sector through effective change management, clear, timely, and transparent communication, as well as adequate funding sources will be critical for other countries planning to transition cervical screening programs.
澳大利亚国家宫颈癌筛查计划从细胞学转变为人类乳头瘤病毒(HPV)的分子检测(当地称为“更新”),包括更长的五年间隔期和起始年龄更大,这对计划实施的所有领域都产生了重大影响。更新对提供该计划服务的病理实验室的角色和要求产生了重大影响。本研究旨在了解更新及其实施对病理部门的早期影响。
在计划过渡后 11-20 个月,对参与利益相关者对更新实施和经验的观点研究(STORIES)的利益相关者(N=49)进行了半结构化定性访谈。对讨论病理部门的部分访谈(N=24)进行了归纳主题分析。
确定了四个总体主题:实施促进因素、挑战、错失的机会和可能的改进。参与者认为,过渡到主要 HPV 筛查的决定是高度可接受和基于证据的,但由于对实验室基础设施、资源、人员配置和财务的影响而面临挑战。这些挑战因对新信息技术(IT)系统不熟悉以及新的国家癌症筛查登记处(“登记处”)在计划过渡日期前尚未完全运行而加剧。有限的自我收集机会和病理表格中缺乏标准化字段被确定为改善该计划公平性的错失机会。为了改进实施过程,参与者建议增加病理部门在规划中的参与度,政府需要提供更及时和透明的沟通,并制定更清晰的临床管理指南。
向主要 HPV 筛查的过渡对澳大利亚病理部门产生了重大且多方面的影响,反映了更新的规模和复杂性。通过有效的变革管理、清晰、及时和透明的沟通以及充足的资金来源为病理部门提供支持的策略对于其他计划过渡宫颈癌筛查计划的国家将是至关重要的。